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Abstract
Asthma belongs to the category of classical allergic diseases which generally arise due to IgE
mediated hypersensitivity to environmental triggers. Since its prevalence is very high in developed
or urbanized societies it is also referred to as "disease of civilizations". Due to its increased
prevalence among related individuals, it was understood quite long back that it is a genetic disorder.
Well designed epidemiological studies reinforced these views. The advent of modern biological
technology saw further refinements in our understanding of genetics of asthma and led to the
realization that asthma is not a disorder with simple Mendelian mode of inheritance but a
multifactorial disorder of the airways brought about by complex interaction between genetic and
environmental factors. Current asthma research has witnessed evidences that are compelling
researchers to redefine asthma altogether. Although no consensus exists among workers regarding
its definition, it seems obvious that several pathologies, all affecting the airways, have been clubbed
into one common category called asthma. Needless to say, genetic studies have led from the front
in bringing about these transformations. Genomics, molecular biology, immunology and other
interrelated disciplines have unearthed data that has changed the way we think about asthma now.
In this review, we center our discussions on genetic basis of asthma; the molecular mechanisms
involved in its pathogenesis. Taking cue from the existing data we would briefly ponder over the
future directions that should improve our understanding of asthma pathogenesis.
Introduction
The realization that asthma is a genetic disorder, which
runs in families, is relatively old and can roughly be dated
back to the early 20th century, where investigators sought
to identify traits with simple Mendelian mode of inherit-
ance responsible for asthma pathogenesis [1]. Later, epi-
demiological surveys were conducted that demonstrated
the heritability of asthma using twin studies [2]. Owing to
the variable phenotypes that asthma presents with [3],
defining it clinically has been challenging and no defini-
tions so far have been fool proof, in terms of sensitivity
and specificity [4]. The definitions and guidelines have
seen transformations from time to time depending upon
our understanding of its etiopathology [5]. Put in its sim-
plest form, asthma is a chronic pulmonary disorder which
is characterized by airway inflammation and remodeling
that leads to reversible airway obstruction [3]. Inflamma-
tion is seen mainly in the larger conducting airways; how-
ever in severe forms of asthma even the smaller airways
show infiltration of immune cells [6]. Asthma represents
a spectrum of disease and apart from symptoms like
wheezing and breathing difficulty; cough, running nose
and eyes, dyspnoea etc. may accompany it with variable
degree and frequency. Inherent genetic factors interact in
complex fashion, with environmental triggers, to bring
about its pathogenesis and depending upon the trigger, it
Published: 6 May 2009
Clinical and Molecular Allergy 2009, 7:7 doi:10.1186/1476-7961-7-7
Received: 20 December 2008
Accepted: 6 May 2009
This article is available from: http://www.clinicalmolecularallergy.com/content/7/1/7
© 2009 Kumar and Ghosh; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
Clinical and Molecular Allergy 2009, 7:7 http://www.clinicalmolecularallergy.com/content/7/1/7is classified as extrinsic or intrinsic asthma [7]. Extrinsic
asthma results from hypersensitivity reactions (such as
wheal and flare reaction to intradermal allergens), result-
ing in increased serum IgE and bronchial hyper-respon-
siveness to specific or non-specific inhaled allergens [7].
In contrast intrinsic asthma is thought to be non-immune
and without any atopic background. We mainly focus on
extrinsic asthma, where there is plenty of genetic data to
build up a sketch of the molecular biology pathways that
play significant role in its pathogenesis. Also, the molecu-
lar mechanisms that these studies have unearthed have
promising therapeutic potentials.
Asthma pathogenesis: a disease of dysregulated immune 
system
Asthma pathology has been traditionally supposed to be
an overenthusiastic response of the immune system to
otherwise innocuous environmental allergens or chal-
lenges. However recent evidences suggest that most of the
allergens that were thought to be innocuous have protease
activity [8,9] or other deleterious effects [10] and our bod-
ies' immune response against them might reflect an ongo-
ing evolution of human beings/other animals with their
environment. In asthma, there is infiltration of mast cells,
basophils, eosinophils, lymphocytes, macrophages etc.
into the bronchial mucosa and these cells along with the
cells of the respiratory tracts such as epithelial cells,
endothelium, smooth muscles etc. bring about airway
inflammation and airway remodeling [3]. Both these
components have hereditary factor and are influenced by
the environment [3].
Since asthma is growing rapidly worldwide in the late
1980s, the "hygiene hypothesis" was proposed to explain
the possible causes of asthma (and other related disor-
ders) based on its increased prevalence in industrialized
societies [11]. It states that lack of microbial fauna during
the early developmental stages leads to immune hyperre-
activity disorders [11]. Later on it was identified that T
helper cell bias towards a Th2 phenotype might be
responsible for asthma pathogenesis [12]. Consequently,
some evidences led scientists to propose that during birth
the immune system is polarized towards Th2 response
while exposure to microorganism during early develop-
mental stages drives the immune response towards Th1
type which is protective against atopic asthma [13,14].
This was established as immunological basis for hygiene
hypothesis [15]. Since then Th1/Th2 polarization has
become the hallmark to explain the causes of asthma [16]
and not surprisingly it has dominated the field of asthma
genetic research for the last two decades. Also, most of the
efforts to discover novel therapeutics to treat or cure
asthma have been centered on this principle [17]. Some
pioneering genetic discoveries in the last few years have
shifted our attention partly to other possible causative
mechanisms and there is growing realization that the
local tissue environment actually plays significant, if not
major role in initiating asthma [18] and plays important
roles in its progression and severity [19].
Approaches to identify genetic components in asthma
Before embarking on to the genetic evidences which have
provided clues regarding the molecular pathways in
asthma, we should take a brief look into the methods used
to fish out susceptibility genes for asthma or complex dis-
orders. We shall not go deep into each of these methods
as excellent reviews already exist for the readers to
acquaint themselves with the latest techniques; biochem-
ical, molecular, analytical [20-23] etc..
Population genetic studies like association studies and
linkage studies have played major roles in identification
of several causative genes for most of the complex disor-
ders including asthma [20,23-25]. Essentially population
genetic studies could be either hypothesis driven, which is
the case in candidate gene studies, or with no prior
hypothesis such as linkage studies. In candidate gene
studies, genes are selected from the pathways shown or
expected to play role in asthma pathogenesis. Candidate
gene studies could be based on allele frequency differ-
ences between affected (cases) and non-affected (control)
individuals known as case-control studies or based on
transmission distortion or disequilibrium of allele(s) as in
family based association studies [25]. Candidate gene
studies are supposed to have high sensitivity to detect alle-
les or variants playing minor role in disease pathogenesis
[21]. On the contrary, linkage studies are usually carried
out with motivation to identify novel disease loci/genes
by genotyping evenly spaced markers in the entire
genome, in large extended families [20]. Since large frac-
tions of genome are shared among individuals in a family,
it is expected that loci with large effects on the phenotypes
could be detected easily and fine mapped to fish out the
susceptibility genes [20,23]. As obvious, sensitivity and
specificity are two vital issues when adopting any of the
two approaches. While the debate continues, develop-
ment of high-throughput array based technologies, with
densely mapped markers, have opened up newer avenues
to perform genome wide association studies that perhaps
should take care of sensitivity and specificity issues in a
better way [22,23].
Other very popular approaches for disease gene identifica-
tion have been microarrays, which take advantage of the
fact that transcripts of various genes can be assayed at
large scale simultaneously [26]. Using both human sub-
jects and animal models a number of studies have been
undertaken that have identified novel genes/pathways or
validated others that play important role in asthma patho-
genesis and may have therapeutic potentials [26]. Com-Page 2 of 9
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pivotal role in identification of genes/molecules involved
in complex diseases [25]. Animal models are suitable as
confounding environmental factors can be better control-
led and tissue samples can be harvested sufficiently with
ease. Also, identical genetic background of the inbred ani-
mal strains allow for dissection of environmental factors
in influencing gene regulation in different pathological
conditions.
It should be appropriate to mention here that a plethora
of genetic association or linkage studies fail to replicate in
different populations, and that tend to frustrate geneticist
as faith in such data has been shrinking. Arguably, as
though, methodological issues pose daunting challenges,
the reason for such variable discoveries could not be
assigned single handedly to poor study designs, as some
very well designed studies have also shown variable
results [27]. In addition, ethnic variation may also
account for such non-replicative results across different
populations. Consequently, hunt for newer technology,
newer analytical tools are on, which should address these
problems in the near future [23,27]. It is unlikely that any
single factor, genetic or environmental, could account for
asthma pathogenesis, therefore statistical tools are being
designed to carryout multifactorial analysis [27]. Also, lots
of efforts are being put to develop cheaper and affordable
sequencing technologies so that sequencing of large
number of individuals can be carried out faster and more
accurately [28]. When sequencing technologies become
cheaper they would facilitate geneticists to include more
individuals to give power and confidence to their observa-
tions and discoveries. Similar revolution in other related
fields like proteomics, lipidomics, epigenomics etc.
should accelerate the identification of genetic compo-
nents and dissection of molecules and pathways relevant
to asthma.
Having set the stage to start our discussion on genes, mol-
ecules and pathways it would be helpful to divide the
available genetic data into two categories; genes that affect
inflammation and genes that play critical role in airway
remodeling events. To caution the readers, it should be
mentioned here that most if not all of the genes could
have multiple roles and take part in both the events. In
fact it has been difficult to study these events in isolation
for all practical reasons as they are tightly connected proc-
esses. However it is desirable for the purpose of making
the discussion simple and interesting. Also, since excellent
reviews are available in this area [20,23-27,29], we would
like to highlight some recent discoveries that have been
discussed less but have great potential for our understand-
ing of asthma pathogenesis and consequently offer oppor-
tunities to design intervention strategies.
Genes influencing the inflammatory pathways
It was around late 1980's and early 1990s, when human
chromosomal regions were first found to be linked with
allergy or asthma [30-32]. Since then various mediators of
inflammation have been identified using approaches
mentioned above [20,23-27,29]. Several genome-wide
screens have found linkage to chromosomal regions, such
as, 5q23-31, 5p15, 6p21.3-23, 11p13, 11p15, 12q14-24.2,
13q21.3, 14q11.2-13, 17p11.1-q11.2, 19q13, 21q21 etc.
[20,23-27,29,33]. The most consistently replicated among
them are 5q23-31, 5p15 and 12q14-24.2 containing genes
like IL-3, IL-4, IL-5, IL-9, IL-12b, IL-13, IFNγ, iNOS,
FCεRIβ etc. [23,33]. Most of these influence the T cell
development/polarization towards Th1 or Th2 besides
modulating other features like recruitment of eosinophils,
mast cells, neutrophils etc. to the site of inflammation
[23,24,33]. These genes have also been validated using
candidate gene approaches in different studies and a
number of functional polymorphisms have been identi-
fied. It was found that the polymorphisms in the intronic
region of IFNγ gene may be critical for IFNγ gene regula-
tion and atopic asthma [34]. Similarly inducible nitric
oxide synthase or iNOS which is expressed predominantly
by immune cells and epithelial cells harbor a number of
promoter and intronic polymorphic repeats that could be
regulating its expression and asthma related traits [35].
Importantly, we had identified an intron 4 repeat to be
associated with asthma severity [35].
Candidate gene approaches have also led to identification
of some important genes that play critical role in asthma
pathogenesis. For example, AMCase or acidic mammalian
chitinase is present on outer coating of several organisms
like fungi arthropods etc. and is found associated with
asthma by our lab [36] and others [37]. Polymorphisms
in FCε RIβ show association across different population
[23]. In Indian population, we had identified protective
and risk haplotypes that regulate IgE mediated histamine
release [38,39]. Several other genes playing role in innate
immune recognition and immunoregulation, antigen
presentation, biosynthesis and regulation of lipid media-
tors, IgE synthesis and regulation, Th2 differentiation and
effector function, and other pathological mechanisms
have been identified and discussed elsewhere [20,23-
27,29,33].
As mentioned earlier T helper cell differentiation play vital
role in asthma pathogenesis. Recently another T helper
subset, namely Th17, has been discovered [40] and the
mechanism of its development, differentiation etc. has
been studied in good detail [41]. While initially discov-
ered to be mediating autoimmune disorders [40], some
recent finding suggest that it might be playing very signif-
icant role in inflammatory pathways critical of asthma
pathogenesis [6,42,43]. IL-17 is the effector cytokine pro-Page 3 of 9
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asthmatic sputum [42]. Recently, Kawaguchi et al have
reported one coding-region sequence variant, His161Arg
substitution in IL-17 gene, which is associated with pro-
tection against asthma [44]. They also demonstrated using
in-vitro studies that this polymorphism inactivates the
ability of this cytokine to activate mitogen-activated pro-
tein kinase, thereby acting as natural antagonist [44].
Th17 cell also secret IL-21 which helps in its differentia-
tion and mediates its effector functions [40]. IL-21 has
been shown to regulate IgE synthesis and it has been
shown that one exonic variant C5250T in exon 3 of this
gene is associated with asthma and serum total IgE [45].
This polymorphism might be affecting mRNA structure as
our bioinformatics results suggest [45]. The role of Th17
in asthma pathogenesis, however, needs further investiga-
tions, as extrapolations from inflammatory event
involved in autoimmune diseases suggest that it could be
playing vital role in its pathogenesis, since it suppresses
the development of regulatory T cells and their action [6].
PI3K plays critical role in the inflammatory events and
shown to modulate multiple features of asthma such as
mast cell development, migration and degranulation,
eosinophil migration and activation, T cell differentia-
tion, B cell activation, IgE synthesis and production etc.
[46,47]. In immune cells PI3K mediates its action through
phosphoinositol 3, 4, 5 tri-phosphate, which acts as mes-
senger and recruits various downstream molecules consti-
tuting a signallosome [47]. Several phosphatases have
been identified that dephosphorylate this lipid messanger
and downregulates PI3K signaling in immune cells [47].
SHIP (src homology 2-containing inositol phosphatase)
is 5' phosphatase and it downregulates mast cell degranu-
tion upon IgE crosslinking, therefore it could regulate
asthma pathogenesis [48]. PTEN (phosphatase and tensin
homologue) which is 3' phosphatase has been shown to
downregulate IL-4, IL-5 and eosinophilic cationic protein
that are expressed in ovalbumin challenged mice [49].
Also, PTEN reduces vascular endothelial growth factor
(VEGF) expression in allergen induced airway inflamma-
tion [50]. Taking lead from differentially expressed genes
in a microarray study in ovalbumin sensitized mice, we
have recently identified inositol polyphosphate 4-phos-
phatase type I (INPP4a), a novel gene associated with
asthma, using population genetics as well as in-vitro and
in-vivo studies [51]. This study lead to the identification
of a non-synonymous SNP +110832 A/G (Thr/Ala) within
a PEST (proline, glutamic acid, serine and threonine)
enriched region to be significantly associated with
asthma. Further, on western blot analysis using human
platelets isolated from human peripheral blood, it was
demonstrated that this polymorphism affects INPP4a sta-
bility, as threonine to alanine substitution, possibly
resulted in less degradation of INPP4a by calpain medi-
ated proteolysis [51]. INPP4a dephosphorylates and inac-
tivates phosphoinositol 3, 4, bis-phosphate preferentially,
another important messanger in the PI3k-akt pathway.
Therefore, SHIP, PTEN and INPP4a seem to be major
players in regulating PtdIns(3,4,5)P3 degradation path-
way and, in our view, hold promising therapeutic poten-
tial. It is very appealing to propose here that these
molecules should be intricately regulated and must be
interacting to keep harmful effects of PI3K at bay; it would
be interesting to empirically demonstrate this. It is also
very logical to propose that INPP4a, being the terminal
enzyme, could play a major role [51].
Genes involved in airway remodeling
Unlike inflammation in asthma, airway remodeling com-
ponent has not received much attention as earlier it was
believed that it appears late in disease process, resulting
from persistent inflammation. However, there are reports
which suggest that airway remodeling events are evident
even prior to the development of disease process in indi-
viduals with asymptomatic AHR [52]. Airway remodeling
refers to the structural changes of the surface of the airway
that lead to its narrowing and constriction. Earlier studies
demonstrated that it might have a role to play in severe
asthma but recent studies suggest that some aspects of it
are present in all forms of asthma at every stage of disease
progression [53,54]. Identification of ADAM33, a disin-
tegrin matrix metalloproteinase 33, was the beginning
that lead researchers to believe that airway remodeling
events are quite distinct and are influenced by genetic fac-
tors. ADAM 33, which is present on chromosome 20, was
identified by positional cloning approach, using linkage
studies in a Caucasian population [55]. Several studies
have replicated this in different populations asserting its
importance [23]. It is expressed by lung fibroblasts and
bronchial smooth muscles but not by bronchial epithelial
or immune cells [56]. ADAM proteins have many
domains and, they have several forms that play various
roles in immune system [56]. The functional role of
ADAM33 is speculative at present and to be demonstrated
experimentally [57]. DPP10 (dipeptidyl peptidase 10) is
another gene that was identified, using positional cloning
approach in mouse and human, to be associated with bro-
chial hyperresponsiveness and IgE [58]. This gene is
located on chromosome 2p14 and encodes for a member
of dipeptidyl peptidase family of proteins and acts to limit
the activity of proteins like cytokines, leukotrienes etc.
which have key roles in asthma pathogenesis [59]. GPRA
(G protein coupled receptor for asthma), which is located
on chromosome 7p15 also shows consistent association
with asthma after its initial linkage to asthma related traits
[60]. GPRA isoforms are differentially expressed in bro-
chial epithelium and airway smooth muscle of asthmatics
and normal controls [60]. SPINK5, on chromosome 5q23-
31, is another gene that might play an important role inPage 4 of 9
(page number not for citation purposes)
Clinical and Molecular Allergy 2009, 7:7 http://www.clinicalmolecularallergy.com/content/7/1/7airway remodeling as it is highly expressed in bronchial
epithelium and consistently shows association with
asthma [18]. The role of TGFβ in airway remodeling is
well documented in genetic [61] and immunological
studies [62]. In Indian population, we had identified spe-
cific haplotypes to be associated with asthma and serum
TGF levels, indicating that polymorphisms play important
role in regulating TGF levels [61]. Taken together, these
data suggest a vital role of tissue remodeling, in asthma
pathogenesis, which is brought about by complex interac-
tion of tissue components like epithelium, smooth mus-
cles etc. These evidences indicate that therapeutic
interventions must be sought for airway remodeling
events which might not be taken care of by the present
therapeutic regimen. Increased prevalence of severe asth-
matics may be explained by the hypothesis that lack of
treatment of airway remodeling during early stages might
make the disease more severe in the later stages. Not sur-
prisingly, some of the genes stated above also show asso-
ciation with severe form of asthma, particularly ADAM33
[63].
Involvement of mitochondria in asthma pathogenesis is
under investigation and receiving considerable attention.
In animal models and human children, increase in mito-
chondrial number and altered mitochondria has been
reported [64,65]. The increase in mitochondrial number
or mitochondrial biogenesis is calcium dependent, regu-
lated by a number of mitochondrial factors [66]. Further,
we have recently demonstrated that mitochondrial struc-
tural changes leading to its dysfunciton plays a critical role
in asthma pathogenesis [67]. Also, mitochondrial dys-
function is IL-4 dependent, since mitochondrial structure
and associated changes, could be reversed by IL-4 mAb
[67]. Additionally, it has been shown that mitochondrial
factors play crucial role in modulating neutrophil survival
in atopic asthmatics [68]. Since there are reports of mater-
nally inherited asthma [69] and mitochondria is believed
to be inherited only from the mother, mitochondrial
genes could be playing an important role in asthma
pathogenesis. From mite induced and uninduced periph-
eral blood mononuclear cells of mite sensitive allergic
patients, Tochigi-ken et al identified 13 differentially
expressed genes using substractive hybridization, 9 of
which were mitochondrial genes [70]. Also, Raby et al
have demonstrated association of a mitochondrial haplo-
group with serum IgE in 654 white children with mild or
moderate asthma [71]. More well designed studies in
future, in different populations, should provide further
evidences on the role of mitochondrial gene polymor-
phisms in contribution to genetics of asthma, since mito-
chondria is critical player in modulating apoptosis [72].
Well, we can definitely be convinced that we know a great
deal about asthma relative to what we knew few years
back, but still, as we have come across throughout the text,
problems loom larger. Asthma seems to be increasing not
only in frequency but also in the intensity or severity of its
affection and that is worldwide phenomena [63]. Severe
or refractory asthma, as it is known, constitutes nearly
10% of asthmatics, which are sizable proportions that
remain uncontrolled or poorly controlled [63]. In fact
knowing more about it, only one thing becomes clear and
that is, we probably are too far from its comprehensive
understanding. Even now, the most preferred therapy
remains the use of steroids and β2-agonist which had been
discovered long time back and, although, their efficacy
has been improved in the past few years, these are mere
symptomatic cure and do not help in managing all kinds
of asthma, besides their reported side effects [73,74].
However it should be mentioned that some excellent
approaches have been attempted at, like allergen specific
immunotherapy or immunotherapy using CpG oligonu-
cleotides to help strengthen the immune system. Also,
some of the candidates like TNF, IFNγ, IL-4, kinases etc.
have been made targets and agonists and/or antagonist
developed/discovered to ameliorate asthma [73,74].
These cytokines/chemokines/kinases etc. have pleiotropic
and/or redundant functions and trying to play with them
seem to be very detrimental to the normal immune home-
ostasis [73,74]. Omalizumab, the humanized anti-IgE
had shown promising results in the clinical trials but it is
very costly and unlike steroids they are not effective
against large sections of asthmatics [75].
These problems, are certainly, not limited to asthma but
other complex disorders as well. The opportunities lie in
trying to capture the complex interaction between mole-
cules and pathways that cause asthma. Very interesting
and logical suggestions have been forthcoming in this
direction and we will discuss some of them briefly.
Gene-gene and gene-environmental interactions; towards 
multifactorial approaches
Asthma is a multigenic disorder and is greatly influenced
by environmental factors, as we have seen in our earlier
discussions. Therefore testing for a single gene or single
factor for accurate prediction of disease outcome is an
unjustified expectation [76-78]. In fact, analyzing for a
single locus for traits that are controlled by multiple loci,
there is considerable loss of power, depending upon the
underlying genetic model used [79]. In a linkage study
involving three ethnic groups from USA, Jianfeng Xu et al
report significant increase in LOD score for several loci in
their gene-gene interaction analyses [80]. For example,
evidence of linkage at 5q31 increase from LOD score 0.98
to 3.21 when analysis was conditioned upon linkage at
1p32 [80]. Other loci such as 12q22, 8p23, 15q13 also
showed increased LOD score when their analyses were
conditioned upon loci that had showed marginal signalsPage 5 of 9
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complemented by affected sib-pair two loci analysis [80].
Several other studies in asthma and other complex disor-
ders suggest that gene-gene interaction studies could
enhance disease outcome prediction when, concurrently,
genes from a pathway or interacting pathway are selected
[81,82]. Similarly, different environmental factors (physi-
cal, chemical, nutritional, behavioral etc.) have been stud-
ied in isolation and shown to affect asthma and related
phenotypes but their interaction effects have been missed
[83]. Environmental factors act like rheostat and influence
gene regulation/expression. We do not inherit disease
state per se but a set of susceptibility genetic factors often
respond to environmental stimuli and predispose individ-
uals to a higher risk group. Our studies, therefore, should
also take into account gene-environment interactions and
its influence on complex diseases like asthma. Polymor-
phisms in 17q21 confer higher risk in early onset asthma
and the risk increases further when there is exposure to
environmental tobacco smoke in early life [84]. This
region contains four genes all of which could have poten-
tial role in asthma pathogenesis [84]. Guerrera S. et al
rightly point out that we have to take a paradigm shift and
design studies that take into account multiple factors that
could be partners in bringing about disease pathogenesis
[27]. Also well planned phenotyping strategies would
greatly enhance outcome prediction in complex heteroge-
neous disease like asthma [27]. However, current analyti-
cal tools have limitations with regard to number of
parameters (genetic/environmental etc) that could be
included in interaction analysis since increase in parame-
ters result in increase in dimensionality of the data. Tradi-
tionally, logistic regression analyses have been performed
to identify interacting partners but they do have limita-
tions since only parameters having independent primary
effect could be tested for interactions. Approaches such as
multifactor dimensionality reduction etc are non-para-
metric tests that could identify interaction even in the
absence of independent primary effects and are becoming
very popular for performing gene-gene and gene-environ-
ment interactions. It is expected that in future low cost
genotyping along with statistical tools that handle high
dimensional data would revolutionize this field.
Epigenetics
Epigenetics, the term, that refers to heritable characters
other than those encoded in the DNA sequence, play
major role in gene-expression [85]. Epigenetic silencing,
which is mediated by DNA methylation, histone modifi-
cations and small RNAs, is influenced by both genetic and
environmental factors [85]. These epigenetic changes
could also be inherited transgenrationally influencing dis-
ease susceptibility [86]. Epigenetic studies have potential
to demonstrate the gene expression changes that occur
during disease processes, for example the epigenetic
changes accompanying T helper cell differentiation
towards Th1 or Th2 have been described [87]. Methyla-
tion changes in the promoter and intronic regions of IL-4
gene have been shown to modulate the production of IL-
4 [88]. Similarly hypermethylation in the IFNγ gene leads
to higher production of IL-4 due to suppressed produc-
tion of IFNγ [89]. These two genes are critical modulators
of Th1/Th2 balance and play vital roles in asthma patho-
genesis. Also, it has been shown that untreated subjects
with asthma possess higher levels of histone acetyltrans-
ferase (HAT) and lower levels of histone deacetylase
(HDAC) in bronchial biopsies which get reversed upon
steroid administration [90]. Similar observations have
also been made for COPD which has many feature com-
mon to asthma. [91]. Parent of origin effect has also been
noted wherein polymorphisms inherited from a particu-
lar parents (father or mother) influence the disease sus-
ceptibility of the offspring [86]. In this regard maternal
prenatal environment seems to play vital role in bringing
about gene expression changes in the offspring [86]. Many
epidemiological studies point towards critical role that
prenatal and early postnatal environmental exposures
could play in bringing about asthma pathogenesis [86].
For asthma which has variable time of onset it has been
proposed that certain epigenetic changes during adult-
hood could also influence the disease onset and progres-
sion [86]. Micro RNAs (miRNAs) have emerged as critical
players of gene regulation, post-transcriptionally and
post-translationally and could be key mediators of epige-
netic regulation [92]. It has been shown that a single
nucleotide polymorphism in HLA-G gene affects binding
of three different miRNAs to this gene [93,94]. Recentally
from our lab it has been demonstrated that miR-106a
brings about post-transcriptional regulation of IL-10 gene
expression. Expression of miR-106a is modulated by tran-
scription factors egr1 and sp1 which binds to miR-106a
promoter [95]. IL-10 is an important candidate gene
found to be associated with asthma in many population
genetic studies [96]. It is worthwhile to note that a
number of miRNAs have been shown to have critical role
in immunity [97]. Till now nearly 300 miRNAs have been
identified and each of them could target hundreds of
genes [98]. Recent development of technologies that ena-
ble high-throughput/genome-wide detection of epige-
netic changes should bring out more data relevant to
asthma and related phenotypes. It should be vital to know
how genetics, environmental factors and epigenetics regu-
late each other and in turn the molecular events that
underlie complex diseases such as asthma.
Copy number variation/polymorphisms
The genomic variation in the human genome ranges from
single nucleotide variation to large microscopically detect-
able variations that have also been shown to be associated
with many disorders [99]. The advancement in the geno-Page 6 of 9
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variation that fall in between these two extremes, known
as copy number variations (CNVs) [99]. Currently all
genomic variations larger than 1 kb of DNA are termed as
structural variations. Structural variants could lead to
change in gene dosage in case of deletion or duplication
etc. or with any change in gene dosage as in inversions or
balanced translocation [99]. Initially identified in case of
sporadic disorders, inherited CNVs have been reported
and associated with many infectious and immunological
disorders like, HIV, systemic lupus erythomatosus, lupus
glomerulonephritis etc. [99]. Various issues related to
identification and analysis of copy number polymor-
phisms are being debated and under modification [100].
However, it has generated enthusiasm among geneticists
as it has potential to explain gene dosage changes in some
of the complex disorders [101-103]. Asthma like other
complex disorders should certainly benefit from this field
and more and more genetic components could be identi-
fied.
Concluding Remarks
In the last few decades the efforts to understand the patho-
physiology of asthma has been intensified due to its
increasing morbidity and mortality. The need to under-
stand the genetics of complex disorders has led to much
advancement in the technologies that have contributed to
our increased understanding of asthma as well. However,
we still have a long way to go, before the available data is
assimilated to design effective intervention strategies and
check asthma menace. We have attempted here to sum-
marize the contribution of genes in asthma and what
pathways these genes belong to. We need to put more
focused efforts to chalk out molecular pathways and draw
a comprehensive map of molecular interactions that
underlie asthma pathogenesis. In this regard, we have out-
lined strategies that should be filling up the missing link
together with possibilities of revolutionary findings.
Although, not very sure where we stand, we definitely are
inching closer and we should identify some novel thera-
peutic strategies that could lead to better asthma manage-
ment and perhaps cure.
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